FindTrial
Sign In

Effect of dexmedetomidine on overall Survival in Colorectal Cancer Patients

Effect of dexmedetomidine on overall Survival in Colorectal Cancer Patients--A multiple retrospective cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200062405
Enrollment
Unknown
Registered
2022-08-04
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

Dex Group:Intraoperative use of dexmedetomidine
Control Group:Intraoperative without dexmedetomidine

Sponsors

The Third Xiangya hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients of the first elective surgery for colorectal cancer (aged 18-65) in adults from January 2018 to December 2018 at Xiangya Third Hospital,301 Hospital and Hunan Cancer Hospital were the subjects of the study.,

Exclusion criteria

Exclusion criteria: (1) ASA grade V or above, (2) general compound intraspinal anesthesia,(3) follow-up abscission.

Design outcomes

Primary

MeasureTime frame
3 years Survival Rate;—

Secondary

MeasureTime frame
WBC counts;—

Countries

China

Contacts

Public ContactOu yangwen
yangwenou@126.com13974934441

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026